@Article{ecn.2012.0311,
AUTHOR = {Ewa Jabłońska, Natalia Wawrusiewicz-Kurylonek, Marzena Garley, Wioletta Ratajczak-Wrona, Bożena Antonowicz, Dorota Dziemiańczyk-Pakieła, Jakub Jabłoński, Adam Krętowski, Stanisława Zyta Grabowska},
TITLE = {A proliferation-inducing ligand (APRIL) in neutrophils of patients with oral cavity squamous cell carcinoma},
JOURNAL = {European Cytokine Network},
VOLUME = {23},
YEAR = {2012},
NUMBER = {3},
PAGES = {93--100},
URL = {http://www.techscience.com/ECN/v23n3/65699},
ISSN = {1952-4005},
ABSTRACT = {Available data indicating a role for neutrophils in the tumor-host reactions are controversial. In 37
patients with oral cavity squamous cell carcinoma (OSCC), we investigated the expression of a tumor-promoting,
proliferation-inducing ligand (APRIL) molecule by peripheral blood neutrophils isolated from blood samples collected
at presentation and three weeks after surgery, and the serum levels of TGF-in the same samples. Additionally,
we investigated the consequences of TLR4 activation by LPS for the synthesis of APRIL by those cells.The levels
of mRNA for APRIL and TLR4 were measured using a real-time PCR method. Western blot analysis was used to
assay the expressions of APRIL and ERK1/2 in cell lysates. The results of the present study revealed the unfavorable
features of the detection, in the blood, of neutrophils displaying an enhanced expression of the tumor-promoting
APRIL molecule. The increased expression and release of APRIL accompanying advanced stages of disease demonstrated
by these cells, combined with the increased number of neutrophils, may be an important marker of disease
progression in the patient group examined. Simultaneously, an increased level of circulating TGF-β in the serum of
these patients appeared to be associated with the overexpression of APRIL in their neutrophils. In contrast to the
healthy controls, TLR4 expression and the ERK1/2 signaling pathway appear to play only minor roles in APRIL
induction in the cells of patients with cancer. The changes presented in the current study suggest that modulation
of the expression of tumor-promoting APRIL, in addition to TRAIL and BAFF, might be taken into account in
the development of new strategies for supportive immunotherapy of OSCC disease and possibly for other types of
neoplasm as well.},
DOI = {10.1684/ecn.2012.0311}
}